Free Trial

Adaptive Biotechnologies (ADPT) 10K Form and Latest SEC Filings 2026

Adaptive Biotechnologies logo
$14.53 +0.10 (+0.70%)
As of 02:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Adaptive Biotechnologies SEC Filings & Recent Activity

Adaptive Biotechnologies (NASDAQ:ADPT) has submitted 605+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Adaptive Biotechnologies's financial statements. The most recent filing was a Form 10-Q submitted on May 5, 2026.

Form 4
Adaptive Biotechnologies Corp Reports Ownership Change on Apr. 29, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Adaptive Biotechnologies Files Quarterly Report on May. 5, 2026

The 10-Q contains Adaptive Biotechnologies's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Adaptive Biotechnologies SEC Filing History

Browse Adaptive Biotechnologies' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/05/2026 3:30 PM
Adaptive Biotechnologies (1478320) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2026 6:08 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:29 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 3:30 PM
Adaptive Biotechnologies (1478320) Filer
Form DEF 14A
04/24/2026 3:31 PM
Adaptive Biotechnologies (1478320) Filer
Form DEFA14A
04/24/2026 3:32 PM
Adaptive Biotechnologies (1478320) Filer
Form ARS
04/21/2026 5:07 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 6:36 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 6:44 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 5:48 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 5:52 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 6:48 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 6:51 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 3:58 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 3:58 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 3:33 PM
Adaptive Biotechnologies (1478320) Subject
LO FRANCIS (1780660) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/06/2026 4:22 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/02/2026 6:16 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 5:56 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 6:41 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 2:12 PM
Adaptive Biotechnologies (1478320) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/23/2026 6:18 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 5:21 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 8:00 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 8:05 PM
Adaptive Biotechnologies (1478320) Subject
BOBULSKY SUSAN (1820885) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 7:53 PM
Adaptive Biotechnologies (1478320) Subject
PISKEL KYLE (1780662) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 7:40 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 7:46 PM
Adaptive Biotechnologies (1478320) Subject
RUBINSTEIN JULIE (1780664) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 7:33 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2026 8:36 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:52 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:55 PM
Adaptive Biotechnologies (1478320) Issuer
BENZENO SHARON (1780854) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:59 PM
Adaptive Biotechnologies (1478320) Issuer
BOBULSKY SUSAN (1820885) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 8:02 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 8:05 PM
Adaptive Biotechnologies (1478320) Issuer
GRIFFIN MICHELLE RENEE (1229765) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:45 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:49 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 7:04 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:53 PM
Adaptive Biotechnologies (1478320) Subject
LO FRANCIS (1780660) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2026 7:29 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:59 PM
Adaptive Biotechnologies (1478320) Issuer
NEUPERT PETER M (1237566) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:49 PM
Adaptive Biotechnologies (1478320) Issuer
HERSHBERG ROBERT (1274139) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:28 PM
Adaptive Biotechnologies (1478320) Issuer
BENZENO SHARON (1780854) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:31 PM
Adaptive Biotechnologies (1478320) Issuer
BOBULSKY SUSAN (1820885) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:35 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:17 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:21 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:25 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:05 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:08 PM
Adaptive Biotechnologies (1478320) Issuer
GRIFFIN MICHELLE RENEE (1229765) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:10 PM
Adaptive Biotechnologies (1478320) Issuer
OWEN KATEY EINTERZ (1852578) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:05 PM
Adaptive Biotechnologies (1478320) Issuer
GRIFFIN MICHELLE RENEE (1229765) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 6:42 PM
Adaptive Biotechnologies (1478320) Issuer
RUBINSTEIN JULIE (1780664) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 6:58 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 6:51 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 4:24 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 4:24 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 3:31 PM
Adaptive Biotechnologies (1478320) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/06/2026 6:30 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 3:15 PM
Adaptive Biotechnologies (1478320) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2026 6:37 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 6:48 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2026 4:09 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 4:24 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/02/2026 4:26 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/14/2026 6:42 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 6:17 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:26 PM
Adaptive Biotechnologies (1478320) Subject
PISKEL KYLE (1780662) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 3:27 PM
Adaptive Biotechnologies (1478320) Subject
LO FRANCIS (1780660) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 7:15 AM
Adaptive Biotechnologies (1478320) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 7:17 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 7:52 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4/A
01/07/2026 7:30 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:52 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:57 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2026 5:22 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/30/2025 7:00 AM
Adaptive Biotechnologies (1478320) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/29/2025 5:27 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 6:06 PM
Adaptive Biotechnologies (1478320) Issuer
LO FRANCIS (1780660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 6:11 PM
Adaptive Biotechnologies (1478320) Issuer
HERSHBERG ROBERT (1274139) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 7:00 PM
Adaptive Biotechnologies (1478320) Issuer
BENZENO SHARON (1780854) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2025 5:30 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 4:15 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/04/2025 3:38 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/03/2025 4:58 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2025 5:45 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 6:27 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 5:03 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/28/2025 12:18 PM
Adaptive Biotechnologies (1478320) Subject
PISKEL KYLE (1780662) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2025 4:30 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 8:39 PM
Adaptive Biotechnologies (1478320) Issuer
BENZENO SHARON (1780854) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 3:58 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144/A
11/21/2025 3:45 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/20/2025 3:25 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 3:22 PM
Adaptive Biotechnologies (1478320) Subject
BENZENO SHARON (1780854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 6:14 PM
Adaptive Biotechnologies (1478320) Issuer
PISKEL KYLE (1780662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 6:19 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS CHAD M (1780649) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 6:30 PM
Adaptive Biotechnologies (1478320) Issuer
ROBINS HARLAN S (1780851) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 7:09 AM
Adaptive Biotechnologies (1478320) Subject
ROBINS CHAD M (1780649) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/10/2025 5:48 PM
Adaptive Biotechnologies (1478320) Subject
ROBINS HARLAN S (1780851) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Adaptive Biotechnologies SEC Filings - Frequently Asked Questions

Adaptive Biotechnologies (ADPT) has submitted 605+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Adaptive Biotechnologies's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Adaptive Biotechnologies's financial statements page.

The most recent filing was a Form 10-Q submitted on May 5, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ADPT) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners